首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1917694

乙肝疫苗市場－2026-2031年預測

Hepatitis B Vaccine Market - Forecast from 2026 to 2031

出版日期: 2026年01月02日 | 出版商:

Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計乙肝疫苗市場將從 2025 年的 78.13 億美元成長到 2031 年的 107.67 億美元，複合年成長率為 5.49%。

乙肝疫苗市場是全球預防性疫苗產業中至關重要且成熟的細分市場，專注於生產和分銷能夠預防B型肝炎病毒（HBV）感染的疫苗。乙肝病毒感染是全球重要的公共衛生議題，也是慢性肝病、肝硬化和肝細胞癌的主要原因之一。這種以B肝表面抗原（HBsAg）為基礎的疫苗能夠高效地預防感染及其嚴重的長期後果。作為公共衛生策略的基石，市場成長得益於各國完善的免疫規劃、全球兒童免疫接種計劃的實施以及在高風險成人人群中持續開展的疫苗接種工作。儘管許多嬰幼兒市場的疫苗覆蓋率較高，但仍存在成長空間，例如透過補種疫苗、成人疫苗宣傳活動以及在以往覆蓋率較低的地區進行接種工作。

疫苗技術和給藥方法

乙肝疫苗是一種重組蛋白疫苗。它是透過將乙肝表面抗原（HBsAg）基因導入酵母細胞而生產的，酵母細胞隨後會產生該抗原。接種後，這種純化的抗原會刺激免疫系統產生保護性抗體，而不會造成實際疾病的風險。此疫苗通常以肌肉注射的方式接種。

標準疫苗接種程序需要接種多劑。嬰兒通常接種三劑（出生時、1-2個月和6-18個月），或接種聯合疫苗（例如，包含白喉、破傷風、百日咳、脊髓灰質炎和b型流感嗜血桿菌的聯合疫苗）。成人可選擇標準的三劑接種程序或加速接種程序。一些新型的兩劑疫苗核准用於特定年齡層，接種方便，依從性更高。市面上也有單價（單一抗原）疫苗和各種多價合併疫苗。

主要市場促進因素

最強勁且持續的促進因素是國家免疫規劃（NIP）的實施和加強。世界衛生組織（WHO）建議全民接種B肝疫苗，大多數國家已將其納入兒童常規免疫接種計畫。這為公共衛生採購機構創造了穩定且可預測的需求，從而構成了市場規模的基礎。

同時，主導政府和國際衛生組織正在進行公共衛生措施和宣傳宣傳活動，旨在提高疫苗接種覆蓋率，優先考慮醫護人員、有多個性伴侶的人和注射毒品的人等高危險成年人群體，並透過針對年齡較大的兒童和青少年的補種疫苗計劃來彌補免疫缺口。

全球乙肝相關疾病負擔沉重，凸顯了疫苗的提案。數百萬慢性感染者面臨肝癌的風險，疫苗的預防作用促使政策制定者支持疫苗接種並持續投入。此外，開發和採用便利的接種方案，例如兩劑疫苗，有助於解決接種依從性問題，並提高青少年和成年人的疫苗接種覆蓋率。

市場挑戰與趨勢

成熟市場面臨的主要挑戰是，現有的國家免疫規劃（NIP）中兒童接種已趨於飽和。這些地區的覆蓋率已經很高，限制了疫苗接種量的成長。成長將依賴成人疫苗接種舉措，但這些計劃面臨許多障礙，例如風險認知不足、接種途徑受限以及其他衛生優先事項。

低收入和中等收入國家在疫苗成本和可及性方面的差距也是一大挑戰。在諸如全球疫苗免疫聯盟（Gavi）等組織的支持下，疫苗可及性已顯著改善，但確保永續的資金籌措和健全的低溫運輸物流仍然是一項持續的挑戰。雖然乙肝疫苗的疫苗猶豫程度低於其他疫苗，但在某些社區，疫苗猶豫仍會影響疫苗覆蓋率目標的實現。

區域市場動態

北美和歐洲是成熟的高價值市場。成長的動力來自新型疫苗配方（包括聯合疫苗和兩劑疫苗）的推出、成人疫苗接種的推薦以及資金充足的公共衛生計畫。這些地區在創新和下一代候選疫苗的研發方面也處於主導。

亞太地區是全球領先的疫苗市場，擁有巨大的成長潛力，這得益於其龐大的人口規模、歷史上較高的疾病負擔，以及中國和印度等國透過國家免疫規劃（NIP）持續努力實現和維持高疫苗接種覆蓋率。此外，該地區還擁有強大的疫苗生產本土基地。

競爭格局與策略重點

該市場呈現寡占格局，由少數幾家大型跨國疫苗生產商主導。競爭主要體現在生產規模與成本效益、疫苗形式（單價疫苗與聯合疫苗）、安全性以及與國際衛生採購組織的合作強度等。

戰略活動涉及多個面向。重點在於結合疫苗的研發與推廣。將乙型肝炎病毒（HBV）抗原納入五價或六價兒童疫苗，可簡化免疫接種程序，並帶來顯著的競爭優勢。製造商也正在投資提高產量和供應鏈可靠性，以滿足全球需求。新一代疫苗正在進行臨床研發，包括潛在的慢性B型肝炎治療性疫苗和具有更廣泛交叉保護作用的疫苗。此外，與公共衛生組織建立策略夥伴關係，簽署長期供應協議，並支持中低收入國家（LMIC）的疫苗宣傳活動，對於確立市場地位至關重要。

市場展望

乙肝疫苗市場預計將保持穩定持續成長，這主要得益於其在全球公共衛生領域不可取代的角色。儘管在許多國家，兒童市場已趨於成熟，但未來的擴張仍將受到多種因素的驅動。

未來成長將日益依賴已開發國家和開發中國家成人及青少年疫苗接種覆蓋率的提高。簡化疫苗接種方案（例如兩劑疫苗）的引入和廣泛應用將為此提供有力支持。在非洲和亞洲部分地區等歷來疫苗覆蓋率較低的地區擴大市場，仍將是全球衛生領域的優先事項。治療性疫苗是一個具有長期潛力的新興領域，但核心的預防性疫苗市場仍將是主要驅動力。

製造商的成功取決於能否維持最高的品質和安全標準，生產最佳化以實現對高所得市場和全球疫苗免疫聯盟（Gavi）支持市場的成本效益供應，以及在其聯合疫苗產品組合中進行創新。作為對抗癌症和肝病主要病因的成熟且經濟有效的干涉措施，乙肝疫苗仍將是全球醫療保健的基石，市場也將不斷發展以解決剩餘的覆蓋缺口和可及性障礙。

本報告的主要優勢：

深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要企業的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
市場促進因素與未來趨勢：探索推動市場的動態因素和關鍵趨勢，以及它們將如何塑造未來的市場發展。
可操作的建議：利用這些見解，在動態環境中製定策略決策，發展新的業務流和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

以下是一些公司如何使用這份報告的範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2022年至2024年的歷史數據和2025年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊）及主要發展動態。

The hepatitis B vaccine market is a critical and mature segment within the global preventative vaccines industry, focused on the production and distribution of immunizations that provide protection against the hepatitis B virus (HBV). HBV infection is a major global health concern, a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma. The vaccine, which is based on the hepatitis B surface antigen (HBsAg), is highly effective in preventing infection and its severe long-term consequences. As a cornerstone of public health strategy, the market's growth is sustained by established national immunization programs, the inclusion of the vaccine in pediatric schedules worldwide, and ongoing efforts to vaccinate high-risk adult populations. While penetration in many infant markets is high, opportunities for expansion remain in catch-up vaccination campaigns, adult immunization, and in regions with historically lower coverage rates.

Vaccine Technology and Administration

The hepatitis B vaccine is a recombinant protein vaccine. It is produced by inserting the gene for HBsAg into yeast cells, which then produce the antigen. This purified antigen, when administered, stimulates the immune system to produce protective antibodies without any risk of causing the actual disease. The vaccine is typically administered via intramuscular injection.

Standard vaccination schedules involve a multi-dose series. For infants, it is often given as a three-dose series (at birth, 1-2 months, and 6-18 months) or incorporated into combination vaccines (e.g., with diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b). For adults, a standard three-dose schedule or an accelerated schedule is used. A newer two-dose vaccine regimen, approved for use in specific age groups, offers improved convenience and compliance. The market also includes monovalent (single-antigen) vaccines and various multivalent combination products.

Key Market Drivers

The most powerful and sustained driver is the implementation and strengthening of national immunization programs (NIPs). The World Health Organization (WHO) recommends universal hepatitis B vaccination, and most countries have incorporated it into their routine childhood immunization schedules. This creates a stable, predictable demand from public health procurement agencies, forming the volume backbone of the market.

Concurrent with this are ongoing public health initiatives and awareness campaigns led by governments and global health organizations. These efforts aim to increase vaccination coverage, target high-risk adult groups (including healthcare workers, people with multiple sexual partners, and injection drug users), and close immunity gaps through catch-up vaccination programs for older children and adolescents.

The high global burden of HBV-related disease underscores the vaccine's value proposition. With millions chronically infected and at risk for liver cancer, the preventative benefit of vaccination drives continued policy support and investment. Furthermore, the development and adoption of convenient dosing regimens, like the two-dose vaccine, help address compliance challenges and expand uptake in adolescent and adult populations.

Market Challenges and Dynamics

A primary challenge in mature markets is saturation in the pediatric segment within well-established NIPs, where coverage rates are already high, limiting volume growth. Growth in these regions becomes dependent on adult vaccination initiatives, which face barriers like lower perceived risk, access issues, and competing health priorities.

The market also contends with cost and access disparities in low- and middle-income countries (LMICs). While support from organizations like Gavi, the Vaccine Alliance has dramatically improved access, ensuring sustainable financing and robust cold chain logistics remains an ongoing challenge. Vaccine hesitancy, though less pronounced for HBV than for some other vaccines, can still impact coverage targets in certain communities.

Regional Market Dynamics

North America and Europe represent mature, high-value markets. Growth is driven by the adoption of newer vaccine formulations (including combination and two-dose vaccines), adult vaccination recommendations, and stable, well-funded public health programs. These regions also lead in innovation and the development of next-generation vaccine candidates.

The Asia-Pacific region is a dominant market in terms of volume and exhibits significant growth potential. This is due to its large population, high historical disease burden, and continued efforts by countries like China and India to achieve and maintain high coverage rates through their NIPs. The region also has a strong local manufacturing base for vaccines.

Competitive Landscape and Strategic Focus

The market is an oligopoly, dominated by a few large multinational vaccine manufacturers. Competition is based on production scale and cost-efficiency, vaccine presentation (monovalent vs. combination), safety profile, and the strength of partnerships with global health procurement agencies.

Strategic activities are multifaceted. A key focus is on developing and promoting combination vaccines. Incorporating HBV antigen into pentavalent or hexavalent pediatric vaccines simplifies the immunization schedule and is a major competitive advantage. Manufacturers also invest in improving production yields and supply chain reliability to meet global demand consistently. There is ongoing clinical development of next-generation vaccines, including potential therapeutic vaccines for chronic HBV infection and vaccines with broader cross-protection. Furthermore, strategic partnerships with public health entities for long-term supply agreements and support for vaccination campaigns in LMICs are critical for market positioning.

Market Outlook

The hepatitis B vaccine market is positioned for steady, sustainable growth, underpinned by its irreplaceable role in global public health. While the pediatric segment in many countries is mature, future expansion will be driven by several factors.

Growth will increasingly come from enhancing adult and adolescent vaccination coverage in both developed and developing nations. The introduction and wider adoption of simplified regimens (like the two-dose vaccine) will support this. Market expansion in regions with historically lower coverage in Africa and parts of Asia remains a priority for global health. While therapeutic vaccines represent a long-term, high-potential frontier, the core prophylactic market will continue to be the mainstay.

Success for manufacturers will depend on maintaining the highest standards of quality and safety, optimizing production for cost-effective supply to both high-income and Gavi-supported markets, and innovating within the combination vaccine portfolio. As a proven and cost-effective intervention against a major cause of cancer and liver disease, the hepatitis B vaccine will remain a fundamental pillar of preventative healthcare worldwide, with its market evolving to address remaining coverage gaps and convenience barriers.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2022 to 2024 & forecast data from 2025 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Key Segment:

By Type
Combination Vaccines
Single Antigen Hepatitis B Vaccines
By Target Population
Infants
Children
Adults
High-Risk Population
By End-User
Hospitals
Clinics
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEPATITIS B VACCINE MARKET BY TYPE

5.1. Introduction
5.2. Combination Vaccines
5.3. Single Antigen Hepatitis B Vaccines

6. HEPATITIS B VACCINE MARKET BY TARGET POPULATION

6.1. Introduction
6.2. Infants
6.3. Children
6.4. Adults
6.5. High-Risk Population

7. HEPATITIS B VACCINE MARKET BY END-USER

7.1. Introduction
7.2. Hospitals
7.3. Clinics
7.4. Others

8. HEPATITIS B VACCINE MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others